The criteria for a booster shot can include your age, job, where you live and your underlying health. In most cases, you have to wait until six months after your first two shots. What’s more, a booster shot doesn’t have to match the first vaccine you had.
As you sort through the maze of information (ideally in coordination with your doctor), remember that even without a booster, the vaccines available in the U.S are very effective.
“People who have gotten a primary series of immunization — whatever it was — need to understand they have very high levels of protection against death, hospitalization and severe disease,” says Dr. Gregory Poland, director of the Mayo Clinic’s Vaccine Research Group.
Confused? Take our quiz to figure out if you need one now.
And read on for more about the science — and continuing debate — around boosters.
A lot of people can get a booster now, but who needs one the most?
People who are 65 or older, people ages 50 to 64 who have certain underlying health conditions and adults 18 or older who live in long-term care settings like nursing homes are all at higher risk of getting COVID-19. The Centers for Disease Control and Prevention says people in all of these groups who got the Moderna or Pfizer-BioNTech vaccines originally should get a booster six months after their initial series.
For anyone 18 or older who got only one shot of the Johnson & Johnson vaccine, the CDC advises that you get a second shot two months after your initial shot — because research shows that this can substantially bump up your protection, rivaling the levels seen with two shots of the mRNA vaccines.
People who are immunocompromised also need to get an additional shot, because data show they often don’t have an effective immune response. This isn’t so much a “booster,” though. It’s just getting them to baseline.
Aside from these groups, it’s a closer call about who needs to get a shot, says Dr. David Dowdy, an infectious disease epidemiologist at the Johns Hopkins Bloomberg School of Public Health. “For the vast majority of people, there’s not an immediate urgency to rush out and get this booster,” he says.
People who live in certain congregate settings, such as homeless shelters and prisons, and people who work in high-risk settings, like health care facilities, schools or grocery stores, may also be at higher risk for COVID-19. This is also true for people 18 to 49 with certain underlying health conditions.
But the CDC’s guidance is not as strong for these groups. You have the option of getting a booster, but whether you decide to get one will depend on factors such as how much the virus is spreading where you live, whether other safety measures are in place, your underlying health and your own individual sense of risk.
If you feel your risk is quite high, then go ahead and get the booster, Dowdy advises. But there’s also an argument for holding off. The extra protection from the booster could serve you well at some point in the future when infections are climbing in your community. “I fall into this category myself, and I’m not in a rush to get a booster shot,” he says.
Is the vaccine really wearing off over time? How concerned should I be?
The protection afforded by the vaccine is waning slightly over time, particularly as the quick-transmitting delta variant circulates, according to studies from the U.S. and other countries, such as Israel. This should not be cause for alarm, though. The most dramatic declines are related to the vaccine’s ability to stop asymptomatic or mild breakthrough infections — for instance, a CDC study of front-line workers found that the vaccines’ effectiveness at preventing infections dropped from 91% (in pre-delta times) to 66% after the delta variant became dominant.
The good news is “we are not seeing a lot of reports of serious disease, hospitalization or death,” says Dial Hewlett, an infectious disease physician at the Westchester County Department of Health in Westchester, N.Y.
In general, the vaccines are still very protective against hospitalization across all age groups. A CDC study published in late September comparing the real-world effectiveness of all three vaccines at preventing hospitalization found Moderna was 93% effective, Pfizer was 88% and J&J was 71%.
But among older adults, the effectiveness appears to be waning slightly. Just how much remains an open debate, and it depends on the vaccine. The Moderna vaccine shows only “mild declines” in vaccine effectiveness against hospitalization among people who are 65 or older. It’s a similar picture for the Pfizer vaccine, although some research shows it may be declining slightly more than Moderna.
The Johnson & Johnson vaccine started at a lower effectiveness against hospitalization than either of the mRNA vaccines, but it’s not yet clear whether that protection is waning like the two others’.
When you consider the slight dip in vaccine protection, keep the context in mind, says Jonathan Golob, an infectious disease physician at the University of Michigan. “The vaccines still remain excellent even for older adults. The one exception is people who are profoundly immunocompromised,” he says.
Is it a good idea to go for a vaccine that’s different from the one I got the first time around?
There are different schools of thought on this “mix and match” strategy. Some Americans may find it attractive for a variety of reasons, but so far the data is very limited.
The good news is that switching to a different vaccine appears quite safe, says Poland, of the Mayo Clinic. “This is a great social and scientific advance to allow people to do a mix-and-match,” he says.
Here’s why Poland supports switching it up. If you had bad side effects from the first vaccine you got, you can now opt for another. Or sometimes it’s just more convenient to get whichever vaccine is first available; you don’t have to fret about finding a particular vaccine if supply is limited. And finally, some of the early research shows you may be better protected, depending on the vaccine you used.
This last reason may apply especially to those who got the J&J vaccine initially. A study from the National Institutes of Health (NIH) recently found that following up the J&J shot with either the Moderna or Pfizer vaccine could produce a stronger immune response than a second dose of J&J’s vaccine. Research from Europe supports this conclusion.
“If it was for me or my family member, I would recommend an mRNA vaccine for those who received J&J,” says Desi Kotis, associate dean at the University of California, San Francisco’s School of Pharmacy.
If you had Moderna for your first two shots, Poland says, you might consider getting the Pfizer booster because it’s a smaller dose (30 micrograms) than the Moderna booster (50 micrograms). This could conceivably cut down on side effects, Poland says, while still providing a very strong immune response. He says he plans to do just this for his booster.
It’s also possible, some experts say, that people who had the Pfizer shots initially will want to chase them with the Moderna booster precisely because the Moderna dose is higher than Pfizer’s — with the idea that this might produce a bigger boost in antibodies.
Still other experts say it could make sense to keep things simple and stick with the original vaccine you received, especially if that worked well for you initially. All the data on boosters is relatively limited, but “we have a much larger experience in people who have received the same product,” says Hewlett.
The bottom line, these scientists agree, is that all these ways of boosting your immunity against COVID-19 are safe and effective.
According to the NIH study, a booster of Moderna following two shots of that same vaccine leads to the highest antibody levels — more than with Pfizer — although it’s probably too small a difference to matter for most groups. Also, the booster dose authorized by the Food and Drug Administration was only half of what was tested in that study.
Either way, scientists still don’t know how different antibody levels translate into overall immunity, so you can’t necessarily assume more is better.
“Nobody knows what the actual level of protection is longer term for all of these different mix-and-match combinations,” says Dowdy.
Are the boosters safe?
Yes. “There’s very, very little risk” of any serious complications from a booster shot, says Kotis, of UCSF. It’s reasonable to assume the “booster could show about the same side effects that you had after those first or second series shots.”
A few specific demographics have an elevated risk of adverse events compared with the general population.
Young men between ages 18 and 25 are at higher risk of myocarditis and pericarditis (inflammation in parts of the heart) following the mRNA vaccines. Research shows the majority of patients who develop this rare condition report feeling better within six weeks though. For the J&J vaccine, women between ages 18 and 49 account for most cases of a severe blood clot, known as TTS. This, too, remains quite rare. In the U.S., there are under 50 reported cases overall out of the 15 million people who’ve received the J&J vaccine.
Still, it’s very reasonable for people who are in these higher-risk demographics to choose a booster based on this concern — i.e., women 18 to 49 could consider choosing one of the mRNA vaccines, and younger men may wish to consider the J&J for their booster.
The bottom line is that all three vaccines are safe for the general population, says Poland. When it comes to safety risks from the vaccines, “we can barely quantify the risk — it’s so low,” he says.
I don’t qualify for a booster. What should I do?
If you are under 65 and without any underlying health problems, the vaccines are really holding up well, says Angela Rasmussen, a virologist at the University of Saskatchewan. “You really don’t need a booster — that is what the data indicates.”
Of course, some people are concerned not only about hospitalization, but also about the chance of getting infected at all. And some studies do show that protection against infection may be dropping for younger adults too.
While this is an entirely valid concern, the vaccines were never designed to stop all infections — only the most severe illness. One day, COVID-19 vaccines may be a three-dose series where everyone gets two priming doses and then a booster, “not because everybody’s at risk, but because we have a lot of vaccines that are three-dose regimens,” says Rasmussen. “It may just be that you do need this third dose to really lock in that long-lasting durability.”
But we’re not quite there yet. In fact, it’s good to keep in mind that the research on boosters is far from settled. “The science is not all that strong right now — it’s still developing,” says Dowdy. “We don’t have long-term data on these boosters, if they provide long-term benefits for protection or even how much protection wanes without a booster.”
NPR’s Pien Huang contributed to this report.